Atyr Pharma Says Post-hoc Analysis Of Phase 1B/2A Study Of Efzofitimod For Pulmonary Sarcoidosis, Shows 7.7% Of Patients In The 3.0, 5.0 mg/kg Efzofitimod Group Relapsed Following Steroid Taper, Compared To 54.4% In Placebo, Efzofitimod 1.0 mg/kg
Portfolio Pulse from Benzinga Newsdesk
aTyr Pharma has announced a post-hoc analysis of its Phase 1B/2A study of Efzofitimod for Pulmonary Sarcoidosis. The results show that only 7.7% of patients in the 3.0, 5.0 mg/kg Efzofitimod group relapsed following steroid taper, compared to 54.4% in the placebo group. The rate of change for forced vital capacity (FVC) was also significantly improved in the Efzofitimod group.
September 11, 2023 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
aTyr Pharma's positive results from the Phase 1B/2A study of Efzofitimod could potentially boost investor confidence and positively impact the company's stock price.
The positive results from the study indicate that Efzofitimod could be a promising treatment for Pulmonary Sarcoidosis. This could potentially lead to increased investor interest in aTyr Pharma, which could drive up the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100